证券代码：603718 证券简称：海利生物 公告编号：2026－002 上海海利生物技术股份有限公司 公司本次回购注销限制性股票将涉及注册资本减少，根据《中华人民共 和国公司法》等相关法律、法规的规定，公司已就上述股份回购注销事项履 行了通知债权人程序，具体内容详见公司于2025年10月30日在证券时报、证 券日报及上海证券交易所网站（www.sse.com.cn）上披露的《上海海利生物 技术股份有限公司关于回购注销部分限制性股票减少注册资本暨通知债权人 的公告》（公告编号：2025-049）。在债权申报期间，公司未收到任何债权 人对此议案提出异议的情况，也未收到任何公司债权人向公司提出清偿债务 或者提供相应担保的要求。 2026年1月7日，公司披露了《上海海利生物技术股份有限公司关于2023 年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告》（公 告编号：2026-001号）。 二、本次限制性股票回购注销实施情况 近日，公司收到了中国证券登记结算有限责任公司上海分公司出具的《 证券变更登记证明》，本次回购注销的限制性股票已过户至公司开立的回购 专用证券账户，并于2026年1月9日完成注销。公司后 ...

Core Viewpoint - The animal health sector experienced a rise of 1.55% on January 9, with significant contributions from leading stocks like Biological Shares, which surged by 4.76% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4120.43, up by 0.92%, while the Shenzhen Component Index closed at 14120.15, up by 1.15% [1]. - The top-performing stock in the animal health sector was Biological Shares (600201), closing at 17.40 with a gain of 4.76% and a trading volume of 683,900 shares, amounting to a transaction value of 1.179 billion yuan [1]. Group 2: Stock Performance Summary - Other notable stocks included: - Shunlian Biological (688098) at 9.67, up by 1.90% with a trading volume of 64,900 shares [1]. - Zhongmu Shares (600195) at 8.10, up by 1.25% with a trading volume of 138,100 shares [1]. - Ruipu Biological (300119) at 19.90, up by 1.12% with a trading volume of 154,700 shares [1]. - Haili Biological (603718) at 6.48, up by 0.78% with a trading volume of 124,600 shares [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 27.3879 million yuan from institutional investors, while retail investors contributed a net inflow of 90.8993 million yuan [2]. - The capital flow for specific stocks showed: - Haili Biological had a net inflow of 10.2913 million yuan from institutional investors [3]. - Jinhe Biological experienced a net inflow of 2.8449 million yuan from institutional investors [3]. - *ST Green Kang (002868) had a net inflow of 1.8780 million yuan from institutional investors [3].

Core Viewpoint - The animal health sector experienced a 0.99% increase on January 8, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4082.98, down 0.07%, and the Shenzhen Component Index closed at 13959.48, down 0.51% [1]. - The animal health sector stocks showed varied performance, with BioShares leading the gains at 3.10% [1]. Group 2: Stock Performance - Key stocks in the animal health sector included: - BioShares (600201) closed at 16.61 with a 3.10% increase and a trading volume of 517,400 shares, totaling 853 million yuan [1]. - Huisheng Biological (300871) closed at 22.46, up 2.23%, with a trading volume of 86,000 shares, totaling 193 million yuan [1]. - Dayu Biological (920970) closed at 8.02, up 2.17%, with a trading volume of 19,900 shares, totaling 15.81 million yuan [1]. - Other notable stocks included PlaiKe (603566) and Shunlian Biological (688098), with increases of 1.90% and 1.71% respectively [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 10.1262 million yuan from institutional investors, while retail investors contributed a net inflow of 37.4241 million yuan [2]. - Notably, the main funds showed a net outflow of 47.5503 million yuan from speculative funds [2]. Group 4: Detailed Capital Flow by Stock - BioShares (600201) had a net inflow of 40.3094 million yuan from main funds, while it experienced a net outflow of 8.4352 million yuan from speculative funds [3]. - Gold River Biological (002688) saw a net inflow of 13.2219 million yuan from main funds, with a net outflow of 3.8181 million yuan from speculative funds [3]. - ST Green Health (002868) had a net inflow of 9.7760 million yuan from main funds, but a significant net outflow of 20.7609 million yuan from speculative funds [3].

关于 2023 年限制性股票与股票期权激励计划 部分限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603718 证券简称：海利生物 公告编号：2026－001 上海海利生物技术股份有限公司 | 回购股份数量 | 注销股份数量 | 注销日期 | | --- | --- | --- | | 375.75万股 | 375.75万股 | 2026年1月9日 | 一、本次限制性股票回购注销的决策与信息披露 回购注销原因：上海海利生物技术股份有限公司（以下简称"公司"）于 2025年10月28日召开第五届董事会第十六次会议，审议通过了《关于公司 2023年限制性股票与股票期权激励计划限制性股票第二个解除限售期解 除限售条件未成就暨调整回购价格及行权价格并回购注销部分限制性股 票与部分股票期权注销的议案》。根据《上市公司股权激励管理办法》（ 以下简称"《管理办法》"）、《上海海利生物技术股份有限公司2023年限 制性股票与股票期权激励计划（草案）》（以下简称"《激励计划》"） 的相关规 ...

Group 1 - The dental medical concept sector rose by 4.97%, ranking fifth among concept sectors, with 25 stocks increasing, including Maipu Medical, Kangtuo Medical, and Lepu Medical, which hit the 20% limit up [1] - The leading gainers in the dental medical sector included Chunli Medical, Haili Biological, and Yirui Technology, which rose by 8.87%, 7.87%, and 6.51% respectively [1] - The stocks with the largest declines were Langzi Co., Weihong Co., and Dongfang Precision, which fell by 0.98%, 0.98%, and 0.83% respectively [1] Group 2 - The dental medical concept sector saw a net inflow of 666 million yuan, with 18 stocks receiving net inflows, and 6 stocks attracting over 30 million yuan in net inflows [2] - Lepu Medical led the net inflow with 485 million yuan, followed by Yinbang Co., Meinian Health, and Haili Biological, which had net inflows of 123 million yuan, 63.16 million yuan, and 46.79 million yuan respectively [2] - The net inflow ratios for Lepu Medical, Haili Biological, and Kangtuo Medical were 18.55%, 15.49%, and 14.12% respectively [3] Group 3 - The top stocks in the dental medical sector based on net inflow included Lepu Medical, Yinbang Co., Meinian Health, and Haili Biological, with respective daily price changes of 19.99%, 4.45%, 3.41%, and 7.87% [3][4] - The trading turnover rates for these stocks were 9.07%, 21.43%, 7.16%, and 7.11% respectively [3][4] - Other notable stocks included Maipu Medical with a 20% increase and a turnover rate of 6.51% [4]

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Group 1 - The core point of the news is that Haili Biological experienced a stock price increase of 5.08%, reaching 6.41 CNY per share, with a total market capitalization of 4.203 billion CNY as of the report date [1] - Haili Biological, established on July 18, 1981, specializes in the research, production, and sales of animal vaccines, with its main business revenue composition being 71.34% from oral vaccines, 28.61% from IVD, and 0.05% from other sources [1] Group 2 - From the perspective of Haili Biological's top ten circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Animal Husbandry ETF (159865), increased its holdings by 3.6987 million shares, totaling 10.2279 million shares, which represents 1.58% of the circulating shares [2] - The Guotai Zhongzheng Animal Husbandry ETF (159865) was established on March 1, 2021, with a current scale of 6.097 billion CNY and has achieved a year-to-date return of 11.41%, ranking 3417 out of 4189 in its category [2]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

本报告依据中国资产评估准则编制 陕西瑞盛生物科技有限公司拟股权收购事宜 涉及的常州天宁龙洋金铂利口腔门诊部有限公司 股东全部权益 资产评估报告 中和谊评报字[2025]60042 北京中和谊资产评估有限公司 二〇二五年十二月三十一日 | 报告编码: 1111020029202500342 | | | --- | --- | | 合同编号: 20256038 | | | 报告类型: | 非法定评估业务资产评估报告 | | 报告文号: | 中和谊评报字 2025 60042 | | 报告名称: | 陕西瑞盛生物科技有限公司拟股权收购事宜涉及的常州天宁龙洋 金铂利口腔门诊部有限公司股东全部权益 | | 评估结论: 5,800,000.00元 | | | 评估报告日: 2025年12月31日 | | | 评估机构名称: | 北京中和谊资产评估有限公司 | | 王芳芳 签名人员: | (资产评估师) 正式会员 编号:11230101 | | 石俊杰 | (资产评估师) 正式会员 编号:14230068 | | 王芳芳、石俊杰已实名认可 | | | ERREARD | | | 声明 | 1 | | --- | --- | ...

本报告依据中国资产评估准则编制 陕西瑞盛生物科技有限公司拟股权收购事宜 涉及的溧阳金铂利口腔门诊部有限公司 股东全部权益 资产评估报告 中和谊评报字[2025]60043 北京中和谊资产评估有限公司 二〇二五年十二月三十一日 | 声明 | 1 | | --- | --- | | 资产评估报告摘要 | 3 | | 资产评估报告正文 | 6 | | 一、委托人、被评估单位和资产评估委托合同约定的其他资产评估报告使用人概况 6 | | | 二、评估目的 | 12 | | 三、评估对象和评估范围 | 12 | | 四、价值类型 | 13 | | 五、评估基准日 | 14 | | 六、评估依据 | 14 | | 七、评估方法 | 17 | | 八、评估程序实施过程和情况 | 25 | | 九、评估假设 | 26 | | 十、评估结论 | 27 | | 十一、特别事项说明 | 29 | | 十二、资产评估报告使用限制说明 | 29 | | 十三、资产评估报告日 | 32 | | 资产评估报告附件 | 34 | 陕西瑞盛生物科技有限公司拟股权收购事宜涉及的 溧阳金铂利口腔门诊部有限公司股东全部权益·资产评估报告 | 报告编 ...